Sayed Feghali
Cardiovascular Disease · Houston, TXNPI 1326040486
Payments from drug & device makers
Across 197 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$910
- Johnson & Johnson$397
- Esperion Therapeutics, Inc.$335
- Amarin Pharma, Inc.$329
- Sanofi-aventis U.S. LLC$327
- Novo Nordisk$315
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,44399%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 31 | $910 |
| Johnson & Johnson(2 entities) | 23 | $397 |
| Esperion Therapeutics, Inc. | 18 | $335 |
| Amarin Pharma, Inc. | 18 | $329 |
| Sanofi-aventis U.S. LLC | 18 | $327 |
| Novo Nordisk | 11 | $315 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $218 |
| Merck | 11 | $191 |
| Boehringer Ingelheim | 9 | $171 |
| E.r. Squibb & Sons, L.L.C. | 8 | $139 |
| Abiomed | 2 | $131 |
| Pfizer | 6 | $126 |
| AstraZeneca | 7 | $125 |
| Heartflow, Inc. | 1 | $125 |
| Abbott | 3 | $115 |
| Novartis | 7 | $111 |
| Actelion Pharmaceuticals US, Inc. | 3 | $92 |
| Kowa Pharmaceuticals America, Inc. | 3 | $74 |
| Arbor Pharmaceuticals, Inc. | 3 | $47 |
| Boston Scientific | 2 | $45 |
| Irhythm Technologies, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Medtronic | 1 | $20 |
| AbbVie | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Avinger Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,472 in reported general payments places this provider in the 50th percentile of 1,515 cardiovascular disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 21 | $13,811 |
| XareltoRivaroxaban | 11 | $12,236 |
| Ezetimibe | 12 | $274 |
| Metoprolol Succinate | 20 | $204 |
| Atorvastatin Calcium | 19 | $188 |
| Losartan Potassium | 17 | $183 |
| Carvedilol | 17 | $165 |
| Amlodipine Besylate | 25 | $149 |
| Hydrochlorothiazide | 13 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $126 | $13,81121 claims |
| Johnson & JohnsonXarelto | $397 | $12,23611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Houston
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- James FeldmanHouston$3.1M
- Aditya SamalHouston$2.6M
- Pranav LoyalkaHouston$2.4M
- Anwar AhmadHouston$1.4M
- Reynolds DelgadoHouston$1.1M
- Richard SmallingHouston$908K
- Amin KarimHouston$853K
- Stephen LittleHouston$806K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.